Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022


Naperville, IL -- (SBWIRE) -- 11/19/2013 -- Reportstack, provider of premium market research reports announces the addition of Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022 market report to its offering
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

The Brazilian type 2 diabetes patient pool is expected to grow significantly due to the increasingly elderly population, insurance coverage and increasing awareness of and emphasis on early diagnosis. Physicians, hospitals and other healthcare providers may be reluctant to purchase the branded drugs if costs are not reimbursed by third-party payers.


Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Brazil from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting Brazil type 2 diabetes market.

Reasons To Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in Brazil

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604